Novavax, Inc. (NVAX)
NASDAQ: NVAX · IEX Real-Time Price · USD
13.85
-1.11 (-7.42%)
At close: Jul 19, 2024, 4:00 PM
14.07
+0.22 (1.59%)
Pre-market: Jul 22, 2024, 7:26 AM EDT
Novavax Employees
Novavax had 1,543 employees as of February 23, 2024. The number of employees decreased by 449 or -22.54% compared to the previous year.
Employees
1,543
Change (1Y)
-449
Growth (1Y)
-22.54%
Revenue / Employee
$645,890
Profits / Employee
-$258,397
Market Cap
1.94B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 23, 2024 | 1,543 | -449 | -22.54% |
Feb 21, 2023 | 1,992 | 451 | 29.27% |
Feb 21, 2022 | 1,541 | 750 | 94.82% |
Feb 24, 2021 | 791 | 626 | 379.39% |
Mar 6, 2020 | 165 | -214 | -56.46% |
Mar 12, 2019 | 379 | 32 | 9.22% |
Mar 9, 2018 | 347 | -8 | -2.25% |
Feb 23, 2017 | 355 | -88 | -19.86% |
Feb 24, 2016 | 443 | 135 | 43.83% |
Feb 23, 2015 | 308 | 95 | 44.60% |
Mar 6, 2014 | 213 | 76 | 55.47% |
Mar 4, 2013 | 137 | 25 | 22.32% |
Mar 8, 2012 | 112 | 24 | 27.27% |
Mar 22, 2011 | 88 | -6 | -6.38% |
Mar 12, 2010 | 94 | 24 | 34.29% |
Mar 10, 2009 | 70 | -16 | -18.60% |
Mar 10, 2008 | 86 | 26 | 43.33% |
Feb 28, 2007 | 60 | 8 | 15.38% |
Mar 6, 2006 | 52 | -108 | -67.50% |
Mar 15, 2005 | 160 | 43 | 36.75% |
Mar 15, 2004 | 117 | -4 | -3.31% |
Mar 28, 2003 | 121 | -52 | -30.06% |
Mar 15, 2002 | 173 | 46 | 36.22% |
Dec 31, 2000 | 127 | 92 | 262.86% |
Dec 31, 1999 | 35 | 19 | 118.75% |
Dec 31, 1998 | 16 | 1 | 6.67% |
Dec 31, 1997 | 15 | -3 | -16.67% |
Dec 31, 1996 | 18 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Amphastar Pharmaceuticals | 1,761 |
Alignment Healthcare | 1,536 |
NovoCure | 1,453 |
LeMaitre Vascular | 630 |
Recursion Pharmaceuticals | 500 |
Immunocore Holdings | 497 |
Arvinas | 445 |
NVAX News
- 27 days ago - Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine - PRNewsWire
- 5 weeks ago - Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine - PRNewsWire
- 6 weeks ago - My Novavax stock price forecast was correct: what next now? - Invezz
- 6 weeks ago - FDA advisers urge targeting JN.1 strain in fall's COVID vaccines - Market Watch
- 7 weeks ago - Novavax to Participate in 2024 Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Novavax awaits FDA decision on whether its next COVID shot can be offered in US - Reuters
- 2 months ago - Shah Capital ends campaign against Novavax board after Sanofi deal - Reuters
- 2 months ago - Up 3x In A Week Will Novavax Stock Continue To See Higher Levels? - Forbes